Discharge Outcomes of Severely Sick Patients Hospitalized with Multidrug-Resistant Tuberculosis, Comorbidities, and Serious Adverse Events in Kyrgyz Republic, 2020–2022
-
Published:2023-06-25
Issue:7
Volume:8
Page:338
-
ISSN:2414-6366
-
Container-title:Tropical Medicine and Infectious Disease
-
language:en
-
Short-container-title:TropicalMed
Author:
Alumkulova Gulzat1, Hazoyan Anna23, Zhdanova Elena1, Kuznetsova Yuliia4ORCID, Tripathy Jaya Prasad5, Sargsyan Aelita2ORCID, Goncharova Olga1, Kadyrov Meder1, Istamov Kylychbek6, Ortuño-Gutiérrez Nimer7ORCID
Affiliation:
1. National Center for Tuberculosis, Bishkek 720020, Kyrgyzstan 2. Tuberculosis Research and Prevention Centre (TBRPC), Yerevan 0014, Armenia 3. Internal Medicine (Gastroenterology and Hepatology) Department, Yerevan State Medical University, Yerevan 0025, Armenia 4. Alliance for Public Health, 01601 Kyiv, Ukraine 5. All India Institute of Medical Sciences, Nagpur 441108, India 6. School of Medicine, Osh State University, Osh City 723500, Kyrgyzstan 7. Damien Foundation, 1081 Brussels, Belgium
Abstract
Patients with multidrug-resistant tuberculosis (MDR-TB) who have comorbidities, complications, and experience serious adverse events (SAEs) are at substantial risk of having unfavorable hospital outcomes. We assessed characteristics and discharge outcomes of 138 MDR-TB patients hospitalized in the National Referral Center of Bishkek, Kyrgyz Republic, from January 2020 to August 2022. The main clinical characteristics included pulmonary complications (23%), malnutrition (33%), severe anemia (17%), diabetes mellitus (13%), viral hepatitis B and C (5%), and HIV infection (3%). Of those patients, 95% were successfully managed and discharged from hospital. Seven patients had unfavorable discharge outcomes (three patients died and four had a worsened clinical condition). Comorbidities (diabetes, and/or HIV), severe anemia, pulmonary complications, cardiovascular disorders, alcohol abuse, and SAEs were associated with unfavorable discharge outcomes. Sixty-five percent of the patients had SAEs, with electrolyte imbalance (25%), gastrointestinal disease (18%), hepatotoxicity (16%), and anemia (14%) being the most frequent. Successful resolution occurred in 91% of patients with SAEs. In summary, our study documented that sick patients who were hospitalized with MDR-TB were well managed and had good hospital discharge outcomes, despite the fact that they had comorbidities, complications, and SAEs. This information should assist in the referral and management of such patients in the future.
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Immunology and Microbiology
Reference22 articles.
1. World Health Organization (2022, May 05). WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment—Drug-Susceptible Tuberculosis Treatment. 24 May 2022 Guideline. Available online: https://www.who.int/publications/i/item/9789240048126. 2. World Health Organization (2022, November 30). Global Tuberculosis Report 2022. Available online: https://www.who.int/publications/i/item/9789240061729. 3. World Health Organization (2022, May 05). Rapid Communication: Key Changes to Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis (MDR/RR-TB). Available online: https://apps.who.int/iris/rest/bitstreams/1420701/retrieve. 4. World Health Organization (2022, May 05). Global Tuberculosis Report 2016. Available online: https://www.who.int/publications/i/item/9789241565394. 5. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis;Maug;Am. J. Respir. Crit. Care Med.,2010
|
|